Oncology News

Oncology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Chang G et al. - In a study to evaluate and compare neurocognitive changes in pts with chronic myelogenous leukemia (CML) or primary myelodysplastic syndrome (MDS) after allogeneic hematopoietic stem cell transplantation (HSCT) or other therapies, it was concluded that time and diagnosis may be important factors when assessing neurocognitive and other changes. Complaints regarding chemobrain after HSCT merit further study, because deficits may predate initiation of treatment and subsequently may improve. The results could reassure prospective HSCT recipients, because HSCT compared favorably with other treatments when mental status side effects were considered.

Methods

Results



Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address